Parameter
| Biomarker | SV2A | Full name | Synaptic Vesicle Protein 2A | Molecular Type | Protein |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prediction, Pharmacodynamics/Response |
| Disease | Epilepsy | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | Tumor Tissue (Immunohistochemistry, PET Imaging) | ||
| Pathobiological Mechanisms | A specific binding target of the anti-epileptic drug levetiracetam; expression levels directly affect drug sensitivity. | ||||
| Clinical Availability Status | Under clinical validation | ||||
| Notes and Dynamics | The response rate to levetiracetam is increased by 30% in patients with high SV2A expression; PET imaging can guide individualized medication. | ||||